Relx Plc $RELX Shares Sold by Journey Strategic Wealth LLC

Journey Strategic Wealth LLC reduced its holdings in Relx Plc (NYSE:RELX) by 29.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,973 shares of the technology company’s stock after selling 2,882 shares during the quarter. Journey Strategic Wealth LLC’s holdings in Relx were worth $379,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. HB Wealth Management LLC grew its position in Relx by 124.6% in the first quarter. HB Wealth Management LLC now owns 19,671 shares of the technology company’s stock worth $992,000 after buying an additional 10,913 shares during the last quarter. LPL Financial LLC boosted its stake in shares of Relx by 9.5% during the 1st quarter. LPL Financial LLC now owns 252,566 shares of the technology company’s stock worth $12,732,000 after acquiring an additional 21,977 shares in the last quarter. Fiera Capital Corp grew its holdings in shares of Relx by 22.9% in the 1st quarter. Fiera Capital Corp now owns 10,411 shares of the technology company’s stock worth $525,000 after acquiring an additional 1,941 shares during the last quarter. Natixis Advisors LLC raised its position in shares of Relx by 0.5% during the first quarter. Natixis Advisors LLC now owns 1,208,467 shares of the technology company’s stock worth $60,919,000 after purchasing an additional 5,875 shares during the period. Finally, Cordatus Wealth Management LLC purchased a new stake in shares of Relx during the first quarter valued at $575,000. 15.02% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RELX has been the subject of a number of recent analyst reports. Wall Street Zen lowered Relx from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Morgan Stanley reaffirmed an “overweight” rating on shares of Relx in a research note on Thursday, September 11th. Barclays reissued an “overweight” rating on shares of Relx in a research report on Tuesday, October 7th. Kepler Capital Markets upgraded shares of Relx from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 18th. Finally, Weiss Ratings downgraded shares of Relx from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Relx presently has an average rating of “Buy”.

Relx Stock Performance

Shares of NYSE RELX opened at $40.63 on Monday. The business’s 50-day moving average price is $44.85 and its two-hundred day moving average price is $49.21. Relx Plc has a one year low of $39.31 and a one year high of $56.33. The company has a debt-to-equity ratio of 2.55, a quick ratio of 0.42 and a current ratio of 0.47.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.